Therapeutic effects of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on non-small lung cell cancer: An experimental with rats

National Medical Journal of China

Volumn 85, Issue 29, 2005, Pages 2021-2025

  Tang, Yan Min ^a   Yang, Shi Fang ^a   Zhu, Bing ^a   Cui, Jun Sheng ^a  

^a Beijing Sunbio Biotech Co Ltd   (China)

Author keywords

Apoptosis; Non small cell lung cancer; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

DNA; RECOMBINANT TUMOR NECROSIS FACTOR; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINCRISTINE;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER TRANSPLANTATION; CONTROLLED STUDY; DNA EXTRACTION; DRUG EFFECT; DRUG MEGADOSE; INJECTION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MICROSCOPY; NICK END LABELING; NONHUMAN; RAT; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; RATS; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 25444481068     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995, 3: 673-682.
2. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem, 1996, 271: 12687-12690.
3. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest, 1999, 104: 155-162.
4. Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther, 2001, 299: 31-38.
5. Walczak H, Miller R, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med, 1999, 5: 157-163.
6. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Neoplasia, 2001, 98: 795-804.
7. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. PNAS, 97: 1754-1759.
8. Yang XH. Cell Apoptosis. In: Wen JK, Han M, eds. Principle and protocols of medical molecular biology. 1st ed. Shanghai: Shanghai Science-populating Publishing House, 1999. 236-237.
9. MacFarlane M. TRAIL-induced signaling and apoptosis. Toxicology Letters, 2003, 139: 89-97.
10. Almasan A, Ashenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine&Growth Factor Reviews, 2003, 14: 337-348.
11. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89: 309-319.
12. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 1998, 273: 14363-14367.
13. Truneh A, Sharma S, Silverman C, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem, 2000, 275: 23319-23325.
14. Diehl GE, Yue HH, Hsieh K, et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity, 2004, 21: 877-889.
15. Smyth MJ, Takeda K, Hayakawa Y, et al. Nature's TRAIL on a path to cancer immumotherapy. Immunity, 2003, 18: 1-6.
16. Frese S, Brunner T, Gugger M, et al. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) - induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. The Journal of Thoracic and Cardiovascular Surgery, 2002, 123: 168-174.
17. Sun SY, Yue P, Zhou JY, et al. Overexpression of Bcl2 blocks TNF-related apoptosis-inducing ligand (TRAIL) -induced apoptosis in human lung cancer cells. Biochemical and Biophysical Research Communications, 2001, 280: 788-797.